Viewing Study NCT00083720

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 4:07 AM

Ignite Modification Date: 2026-02-25 @ 8:48 PM

Study NCT ID: NCT00083720

Status: COMPLETED

Last Update Posted: 2011-05-25

First Post: 2004-05-28

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

Sponsor: Eli Lilly and Company

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Adverse Events Module Baseline Characteristics Module Participant Flow Module